Welcome to
Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

  • Björn Sjöstrand Björn Sjöstrand
  • Björn Gustavsson Björn Gustafsson
  • Tobias skarin Tobias Skarin
  • Peter Liss sv Peter Liss
  • mikael_vikström Mikael Vikström
  • helena_päärni Helena Päärni

Scandinavian Biopharma continues to grow – 2016 was another successful year

2017-06-08

2016 was another successful year with continued strong growth for Scandinavian Biopharma. For the distribution business, which are conducted through the subsidiary Scandinavian Biopharma Distribution, revenue growth landed at impressive 43%. At a group level the growth was 7 % in 2016 as revenues increased from 44,2 million SEK in 2015 to 47,3 million SEK […]

Our collaboration partner, Jan Holmgren, is awarded the world’s greatest vaccine prize

2017-04-27

This week, Dr. Jan Holmgren received the 24th annual Albert B. Sabin Gold Medal Award in honor of his pioneering work in mucosal immunology and leadership in the development the world’s first oral cholera vaccine. Awarded annually since 1994, the Albert B. Sabin Gold Medal Award recognizes a researcher who has made extraordinary contributions in the […]

Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb

2017-04-21

Scandinavian Biopharma today announces that the company has entered into an exclusive agreement with Flynn Pharma for the viper antivenom ViperaTAb. Under the new agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany. “We are very pleased to strengthen our portfolio […]